Clinical Pharmacy Services Publications

Title

Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in the treatment of peritoneal carcinomatosis

UMMS Affiliation

Commonwealth Medicine, Clinical Pharmacy Services; Department of Surgery

Date

6-19-2009

Document Type

Article

Medical Subject Headings

Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; dosage; Carcinoma; Cisplatin; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; Middle Aged; Mitomycin; Neoplasm Invasiveness; Peritoneal Neoplasms; Quality of Health Care; Retrospective Studies; Survival Rate

Disciplines

Pharmacy and Pharmaceutical Sciences

Abstract

PURPOSE: Cytoreductive surgery (CS) and intraperitoneal hyperthermic chemotherapy (IPHC) in the treatment of peritoneal carcinomatosis (PC) in 15 patients are described.

SUMMARY: Fifteen patients with PC who were treated with CS and IPHC were retrospectively identified between January 2002 and December 2006. All patients underwent cytoreduction immediately followed by IPHC with mitomycin or cisplatin. The time between undergoing CS and IPHC and the date of the last follow-up appointment or the date of death was used to calculate survival data for each patient. Nine patients had complete cytoreduction, and all but one patient had evidence of invasive disease at the time of surgery. Eleven patients required concomitant bowel resection at the time of debulking. Thirteen patients required blood transfusions during the perioperative period. Nine patients were discharged home, and four were discharged to a rehabilitation facility. Two patients died during the perioperative hospital admission, both of whom had a preoperative Eastern Cooperative Oncology Group (ECOG) performance status score of 2. The median survival time was 8.4 months, similar to the findings of previously published studies. Further studies are needed to see if tumor type, ECOG performance status score, degree of cytoreduction, and the chemotherapy agent used in IPHC can be correlated to quality of life and survival in patients with heterogeneous primary sources of intraabdominal malignancies.

CONCLUSION: Combination treatment with CS followed by IPHC in 15 patients with heterogeneous primary sources of intraabdominal malignancies resulted in a median survival time of 8.4 months.

Rights and Permissions

Citation: Am J Health Syst Pharm. 2009 Jul 1;66(13):1186-90. Link to article on publisher's site

Related Resources

Link to Article in PubMed